WellSpring Completes $3M Capital Investment, Forms New Partnership

Apr 07, 2016

WellSpring Pharma Services has announced a $3 million capital investment in new equipment as well as a new strategic partnership with IDT Australia Ltd. to manufacture drugs targeting the U.S. market.

The capital investment enables new, directly scalable capabilities in smaller development-scale equipment; expanded manufacturing for specialized dosage forms such as bilayer tablets; and improved support for high-potency compound manufacturing.

“Our expanded capabilities include new expertise in process development and manufacturing for earlier phased clinical trials as well as future expansion of our large-scale manufacturing capabilities,” said David Mayers, president, WellSpring Pharma Services. “We’re now better equipped to offer our clients services from small-scale development and scale-up to large-scale manufacturing, packaging and distribution.”

Among the equipment added during the capitalization were an Alexanderwerk Roller Compactor; an IMA Precisa capsule weight checker; a 400 kg O’Hara Tray Drying oven; a Korsch XL 400 Tablet Press with bilayer module; a Glatt GPCG 2/5 Fluid Bed Processor; an O’Hara Aqueous Film Coater with 18” and 30” interchangeable pans; and a 5L Becomix Counter sweep vessel.

Motivated in part by WellSpring’s expanded capabilities, IDT Australia concluded a manufacturing and supply agreement to produce several products at the WellSpring facility near Toronto, including Pindolol, a cardiac drug with an estimated U.S. market value of $10 million.